Keywords: Bayer, ZymoGenetics, Recothrom, Rights returned

Bayer returns most rights to Recothrom to ZymoGenetics

Article | 22 December 2009

Print This

German drugs major Bayer has returned most of the rights it acquired in 2007 to US firm ZymoGenetics’ Recothrom (thrombin alfa, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in